When Peter Rich was diagnosed with stage 4 prostate cancer at age 59, he asked a tough question for one very distinct reason.
“I said, ‘Doc, am I going to die from this?’ When she said yes, I asked how long. I want to talk in terms of that so I can prove you wrong,” Rich says.
He has. Despite the 30-month average survival time for metastatic prostate cancer, he’s now been living with cancer for six years.
Rich has been through a number of different treatments – radiation, chemotherapy, abiraterone, PARP inhibitor, and numerous clinical trials, all under the care of Kathleen Cooney, M.D., his oncologist at the University of Michigan Comprehensive Cancer Center. He currently takes Xtandi (enzalutamide), which is designed to interfere with the hormone androgen. It’s four pills a day, and it makes him tired so he takes two naps each day.